A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

详细信息    查看全文

• 作者：Clamp ; A. ; Adams ; M. ; Atkinson ; R. ; Boven ; E. ; Calvert ; A.H. ; Cervantes ; A ; Ganesan ; T. ; Lotz ; J. ; et. al.
• 关键词：Ovarian cancer ; Exatecan mesylate ; Topoisomerase I ; Clinical trial
• 刊名：Gynecologic Oncology
• 出版年：2004
• 出版时间：October, 2004
• 年：2004
• 卷：95
• 期：1
• 页码：114-119
• 全文大小：112 K

文摘

There is an urgent need for new agents with activity in platinum- and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer.